KalVista Pharmaceuticals, Inc.

KalVista is a pharmaceutical company focused on the discovery, development and commercialization of small molecule protease inhibitors as new treatments for diseases with significant unmet need.Our initial focus is on inhibitors of plasma kallikrein, which is an important component of the body’s inflammatory response and which, in excess, can lead to increased vascular permeability, edema and inflammation. We have developed a proprietary portfolio of novel, small molecule plasma kallikrein inhibitors initially targeting hereditary angioedema (HAE) and diabetic macular edema (DME).

Bank Name KalVista Pharmaceuticals, Inc.
Stock Exchange NASDAQ
Symbol KALV
Sector Healthcare
Industry Major Pharmaceuticals
Country United States
World Region Amarica
CEO Mr. Thomas Andrew Crockett
Employees 28
Website www.kalvista.com
Registered Year